title: Secukinumab for the Treatment of Deficiency of Interleukin 36 Receptor Antagonist in an Adolescent.
authors.affiliation: Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel2The Center for Genetic Diseases of the Skin and Hair, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: Vered
authors.initials: V
authors.lastname: Molho-Pessach
authors.affiliation: Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: Rinad
authors.initials: R
authors.lastname: Alyan
authors.affiliation: Faculty of Medicine, Hebrew University, Jerusalem, Israel.
authors.forename: Danielle
authors.initials: D
authors.lastname: Gordon
authors.affiliation: Jenin Health Directorate, Palestinian Ministry of Health, Palestinian Authority, West Bank.
authors.forename: Hussein
authors.initials: H
authors.lastname: Jaradat
authors.affiliation: Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel2The Center for Genetic Diseases of the Skin and Hair, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: Abraham
authors.initials: A
authors.lastname: Zlotogorski
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007279:Injections, Subcutaneous; D007378:Interleukins / Q000097:blood / Q000172:deficiency*; D008297:Male; D011565:Psoriasis / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D012867:Skin / Q000473:pathology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C122187:IL36RN protein, human; D007378:Interleukins; C555450:secukinumab